Abstract
Prevalence of SARS-CoV-2 antibodies is an essential indicator to guide measures. Few population-based estimates are available in Germany. We determine seroprevalence allowing comparison between regions, time points, socio-demographic and health-related factors.
MuSPAD is a sequential multi-local seroprevalence study. We randomly recruited adults in five counties with differing cumulative SARS-CoV-2 incidence July 2020 - February 2021. Serostatus was determined using Spike S1-specific IgG ELISA. We determined county-wise proportions of seropositivity. We assessed underestimation of infections, county and age specific infection fatality risks, and association of seropositivity with demographic, socioeconomic and health factors.
We found seroprevalence of 2.4 % (95%CI: 1.8-3.1%) for Reutlingen in June 2020 (stage 1) which increased to 2.9% (95%CI: 2.1-3.8%) in October (stage 2), Freiburg stage 1 1.5% (95% CI: 1.1-2.1%) vs. 2.5% (95%CI: 1.8-3.4%), Aachen stage 1 2.3% (95% CI: 1.7-3.1%) vs. 5.4% (95%CI: 4.4-6.6%), Osnabrück 1.3% (95% CI: 1.0-1.9%) and Magdeburg in Nov/Dec 2020. 2.4% (95%CI 1.9-3.1%). Number needed to quarantine to have one infected person quarantined was 8.2. The surveillance detection ratio (SDR) between number of infections based on our results and number reported to health authorities ranged from 2.5-4.5. Participants aged 80+ had lower SDR. Infection fatality estimates ranged from 0.2-2.4%. Lower education was associated with higher, smoking with lower seropositivity.
Seroprevalence remained low until December 2020 with high underdetection. The second wave from November 2020 to February 2021 resulted in additional 2-5% of the population being infected. Detected age specific differences of SDR should be taken into account in modelling and forecasting COVID-19 morbidity.
Evidence before this study Seroepidemiological surveys on SARS-CoV-2 are a useful tool to track the transmission during the epidemic. We searched PubMed/the pre-print server medRxiv and included web-based reports from German health organizations using the keywords “seroprevalence”, “SARS-CoV-2”, “Germany” and similar other English and German terms in the period from January 1st, 2020 until March 2021. We identified 30 published studies in Germany which mostly report low SARS-CoV-2 seroprevalence (<5%). Most of these surveys were so-called hotspot studies which assessed seroprevalence after localized outbreaks or examined seroprevalence of specific population groups such as e.g. medical staff. Few studies are either population-based or blood donor-based, but do not allow comparisons between regions. To date, we only consider the Corona sub-study of the Rhineland study similar to MuSPAD. It reports a low SARS-CoV-2 seroprevalence (46/4755; 0.97%; 95% CI: 0.72−1.30). Based on this, almost the entire German population remained susceptible to a SARS-CoV-2 infection by the end of 2020.
Added value of this study We provide the first comprehensive, high-precision multi-region population-based SARS-CoV-2 seroprevalence study with representative sampling following the WHO protocol in Germany. By measuring SARS-CoV-2 IgG, we explore immunity at regional and national level over time. We also assess risk factors and sample each region twice, which permits to monitor seroprevalence progression throughout the epidemic in different exemplary German regions.
Implications of all the available evidence Our results show low seroprevalence (<3%) until Mid-December 2020 in all regions. While estimates in Reutlingen, Aachen, Freiburg and Osnabrück reflect low seroprevalence mostly after the first wave, the survey in Magdeburg cumulatively already represents the beginning of the second wave. The number needed to quarantine to ensure one infected person was quarantined was 8.2 in our study. We also show that for the first wave reported infections reflected overall around 25% of those actually infected rising to 40-50% in the second wave. A slightly raised infection risk could be shown for persons with lower education.
Competing Interest Statement
This work was supported by The Helmholtz Association, European Union's Horizon 2020 research and innovation programme [grant number 101003480] and by intramural funds of the HZI
Clinical Trial
Trial registration: ID DRKS00022335 at DRKS (German Clinical Trials Register).
Funding Statement
This work was supported by The Helmholtz Association, European Union's Horizon 2020 research and innovation programme [grant number 101003480] and by intramural funds of the HZI
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MuSPAD complies with all relevant laws and declarations (EU Charter of Fundamental Rights, Biomedical Convention of the Council of Europe and additional protocols, the CIOMS guidelines and the Helsinki Declaration), ethical approval was given on 21.06.2020 by the Ethics Committee of the Hannover Medical School (Ethics approval no 9086_BO_S_2020).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* shared first authorship
Data Availability
The data used for this study can be made available anonymized to other academic researchers. Available data variables shared with the applicant will be: study site information, recruitment status, essay information, bio sample type, demographic information, self-administered diagnostic anamneses and seroprevalence test results. For more details please contact muspad{at}helmholtz-hzi.de. Academic institutions can apply for the data via serohub{at}helmholtz-hzi.de. The serohub is the seroprevalence virtual research environment that stores case based information of the MuSPAD study and other (inter-)national studies. The application process includes the review of the targeted research question and research method. After approval, a link to share the data will be send to the applicant. Shared data will be in regards to international data standards (for more details see https://www.covid19dataportal.org/support-data-sharing-covid19 in csv format.
